The US Food and Drug Administration has approved the first medication for a common form of liver inflammation called nonalcoholic steatohepatitis, or NASH, the agency said Thursday. NASH — also known ...
Standard MM.6.10 (formerly TX.3.9) The effects of medication(s) on patients are monitored. The rationale for this standard is that monitoring helps to ensure that drug therapy is appropriate and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback